Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm

Model scores of the 29,894 trials active now.

Model score 29% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerprostateconcurrentchemotherapycells
  Phrases that lowered it: patientsmgadultgroupimmune
• Drug's FAERS reports with a death: 28.9% (raises risk) · Drug's FDA history
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Sponsor's past termination rate: 9.0% (raises risk) · Sponsor's track record
• Sponsor's past trials: 156 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Number of arms: 1 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 75 (lowers risk) · Sponsor's track record
• Maximum age: 64 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS NCT00839982 · started 2008 · scored riskier than 84% of active trials completed
• Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease NCT00863434 · started 2009 · scored riskier than 83% of active trials terminated
• Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia NCT00814164 · started 2008 · scored riskier than 56% of active trials terminated
• Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia NCT00708721 · started 2008 · scored riskier than 99% of active trials terminated
• Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years NCT01193400 · started 2010 · scored riskier than 82% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.